Corvus Pharmaceuticals (CRVS) Non-Current Deffered Revenue (2015 - 2018)

Corvus Pharmaceuticals' Non-Current Deffered Revenue history runs 4 years deep, the most recent figure standing at $869000.0 for Q4 2018.

• On a quarterly basis, Non-Current Deffered Revenue fell 9.48% year-over-year to $869000.0 in Q4 2018; TTM through Dec 2018 was $869000.0, a 9.48% decrease from a year earlier, with the FY2018 full-year figure at $869000.0, down 9.48% from the prior year.
• Non-Current Deffered Revenue grew to $869000.0 in Q4 2018 per CRVS's latest filing, from $627000.0 in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $1.4 million in Q4 2016 and bottomed at $627000.0 in Q3 2018.
• The 4-year median for Non-Current Deffered Revenue is $1.1 million (2017), against an average of $1.0 million.
• Across the five-year window, Non-Current Deffered Revenue jumped 113.4% in 2016 and slumped 41.02% in 2018, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $642000.0 in 2015, then surged by 113.4% to $1.4 million in 2016, then declined by 29.93% to $960000.0 in 2017, then declined by 9.48% to $869000.0 in 2018.
• Per Business Quant, the three latest CRVS Non-Current Deffered Revenue figures stand at $869000.0 (Q4 2018), $627000.0 (Q3 2018), and $738000.0 (Q2 2018).